What does ReproNovo do?
ReproNovo is a biopharmaceutical company based in Lausanne, Switzerland, dedicated to developing innovative treatments in reproductive medicine and women's health. The company is developing its lead clinical compounds, RPN-001 for treating male infertility and RPN-002, a first-in-disease approach to manage adenomyosis and improve embryo implantation during assisted reproductive technology treatments.
How much did they raise?
The company raised $65M in Series A financing, with the round led by Jeito Capital and co-led by AXA IM Alts along with founding investor M Ventures. Additional participation came from Ysios Capital and ALSA Ventures.
What are their plans for the money?
With the funds, ReproNovo plans to advance its pipeline by progressing multiple Phase 2 programs. The investment is expected to bolster clinical development efforts, accelerating the journey of their promising compounds towards potentially transformative treatments in reproductive health.
What have they achieved so far?
ReproNovo has already achieved significant milestones by advancing both of its primary assets, RPN-001 and RPN-002, to Phase 2 readiness. The company also benefits from having development hubs in Copenhagen and Barcelona, which support its ambitious pipeline.
